Skip to main content

and
  1. Article

    Open Access

    18F-florbetaben Aβ imaging in mild cognitive impairment

    18F-florbetaben and positron emission tomography were used to examine the relationships between β-amyloid (Aβ) deposition, cognition, hippocampal volume, and white matter hyperintensities in mild cognitive impai....

    Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs in Alzheimer's Research & Therapy (2013)

  2. Article

    Open Access

    Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies

    The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET studies hav...

    Michelle T Fodero-Tavoletti, Shozo Furumoto in Alzheimer's Research & Therapy (2014)

  3. Article

    Open Access

    Imago Mundi, Imago AD, Imago ADNI

    Since the launch in 2003 of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in the USA, ever growing, similarly oriented consortia have been organized and assembled around the world. The various accompl...

    Victor L Villemagne, Seong Yoon Kim, Christopher C Rowe in Alzheimer's Research & Therapy (2014)

  4. Article

    Open Access

    Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease

    The Centiloid scale was developed to standardise the results of beta-amyloid (Aβ) PET. We aimed to determine the Centiloid unit (CL) thresholds for CERAD sparse and moderate-density neuritic plaques, Alzheimer...

    Sanka Amadoru, Vincent Doré, Catriona A. McLean in Alzheimer's Research & Therapy (2020)

  5. Article

    Open Access

    Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

    β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous researc...

    James D. Doecke, Larry Ward, Samantha C. Burnham in Alzheimer's Research & Therapy (2020)

  6. Article

    Open Access

    Early detection of amyloid load using 18F-florbetaben PET

    A low amount and extent of Aβ deposition at early stages of Alzheimer’s disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the popul...

    Santiago Bullich, Núria Roé-Vellvé, Marta Marquié in Alzheimer's Research & Therapy (2021)

  7. Article

    Open Access

    Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

    CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profil...

    James D. Doecke, Cindy Francois, Christopher J. Fowler in Alzheimer's Research & Therapy (2021)

  8. Article

    Open Access

    Mesial temporal tau in amyloid-β-negative cognitively normal older persons

    Tau deposition in the mesial temporal lobe (MTL) in the absence of amyloid-β (Aβ−) occurs with aging. The tau PET tracer 18F-MK6240 has low non-specific background binding so is well suited to exploration of earl...

    Natasha Krishnadas, Vincent Doré, Colin Groot, Fiona Lamb in Alzheimer's Research & Therapy (2022)